Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres
WOBURN, Mass., Feb. 26, 2021 /PRNewswire/
Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, received positive guidance from the National Institute for Health and Care Excellence (NICE) regarding the use of selection internal radiation therapy (SIRT) with SIR-Spheres Y-90 microspheres for the treatment of adults with unresectable advanced hepatocellular carcinoma (HCC).
NICE recommends the use of SIRT using SIR-Spheres in England and Wales as a fully funded and reimbursed option for adult patients with HCC, on the conditions that it is used for people with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and that the company provides SIR-Spheres according to the commercial arrangement.
Sirtex Medical announces collaboration update with OncoSec Medical
News provided by
Share this article
TAVO™ for the treatment of advanced melanoma
WOBURN, Mass., Jan. 19, 2021 /PRNewswire/
Sirtex Medical US Holdings, Inc. ( Sirtex ), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
The collaboration update provides Sirtex with the option to acquire the right to co-promote TAVO™ and its related EP gene delivery system in the United States in the lead target indication of treating anti-PD-1 refractory locally advanced or metastatic melanoma. Sirtex has the right to exercise the option until 90 days following the filing of a Biologics License Application (BLA) by OncoSec.